Multi Omics Integration Reveals Treatment and Plaque Dependent Molecular Signatures in Biologic Naïve Rheumatoid Arthritis Patients Receiving csDMARDs, TNF Inhibitors or Baricitinib (ACR Convergence 2026) - Sep 8, 2026 - Abstract #2022; Pres time: Nov 10, 2026; 10:30 AM - 12:30 PM; Location: WB1&2; In Person; "Multi‑omic integration reveals treatment‑ and CIMT‑dependent molecular signatures in RA, with drug‑specific modulation of inflammatory and lipid pathways in patients with versus without carotid plaque, supporting a role for pre‑existing subclinical atherosclerosis in shaping the cardiovascular impact of csDMARDs, TNFi and Baricitinib. Supported by Lilly (I4V-NS-0032), ISCIII (FI22/00299, FI25/00087, PI24/00959, CP25/00109 and RICORS: RD24/0007/0019), and RYC2021-033828-I; co-financed by European Union."
Clinical • Atherosclerosis • Cardiovascular • Immunology • Inflammatory Arthritis • Rheumatoid Arthritis • Rheumatology • ANGPT1 • CXCL10 • IL1R1 • IL2 • IL6 • JAK1 • KRAS • STAT3 • STAT5 • TGFB1
|
|
Laura Muñoz-Barrera1; Alexandra E Oppong2; Rafaela Ortega-Castro3; Sagrario Corrales Díaz-Flores4; Jerusalem Calvo5; Concepción Aranda-Valera6; Maria Lourdes Ladehesa Pineda7; Junjie Peng8; Ismael Sánchez Pareja9; MºCarmen Ábalos-Aguilera10; Christian Merlo11; Mº Ángeles Aguirre Zamorano12; Pedro Seguí13; Tomás Cerdó14; Nuria Barbarroja15; Rocío González Conejero16; Constantino Martínez16; Carlos Perez-Sanchez17; George A Robinson18; Elizabeth C Jury19; Chary Lopez-Pedrera20; Alejandro Escudero Contreras21
|